Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 2/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2873174 | 0.91 | ITGB1 (0.48) | ITGB1ITGA4KDM4EMAPTTHRB | |
| SCHEMBL2872923 | 0.91 | ITGB1 (0.48) | ITGB1ITGA4KDM4EMAPTTHRB | |
| SCHEMBL2408947 | 0.91 | ITGB1 (0.48) | ITGB1ITGA4KDM4EMAPTTHRB | |
| SCHEMBL24378315 | 0.89 | ITGB1 (0.44) | ITGB1ITGA4KDM4EMAPTTHRB | |
| SCHEMBL12807816 | 0.89 | MAPT (0.42) | ITGB1ITGA4KDM4EMAPTTHRB | |
| SCHEMBL20850498 | 0.89 | MAPT (0.42) | ITGB1ITGA4KDM4EMAPTTHRB | |
| SCHEMBL20830443 | 0.89 | MAPT (0.42) | ITGB1ITGA4KDM4EMAPTTHRB | |
| SCHEMBL9802984 | 0.89 | MAPT (0.42) | ITGB1ITGA4KDM4EMAPTTHRB | |
| SCHEMBL13696412 | 0.85 | MAPT (0.39) | ITGB1ITGA4KDM4EMAPTTHRB | |
| SCHEMBL26234723 | 0.85 | MAPT (0.39) | ITGB1ITGA4KDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200385342-A1 | Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress | NACUITY PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385342-A1 | Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress | SNCA, ACAA2, CRYAA | ITGB1 676/4885ITGA4 1069/4885KDM4E 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.